Kooijman M - Search Results

1

Contribution of animal studies to evaluate the similarity of biosimilars to reference products.

van Meer PJ, Ebbers HC, Kooijman M, Gispen-de Wied CC, Silva-Lima B, Moors EH, Schellekens H. van Meer PJ, et al. Among authors: kooijman m. Drug Discov Today. 2015 Apr;20(4):483-90. doi: 10.1016/j.drudis.2014.11.009. Epub 2014 Nov 20. Drug Discov Today. 2015. PMID: 25463036 Review.

2

The ability of animal studies to detect serious post marketing adverse events is limited.

van Meer PJ, Kooijman M, Gispen-de Wied CC, Moors EH, Schellekens H. van Meer PJ, et al. Among authors: kooijman m. Regul Toxicol Pharmacol. 2012 Dec;64(3):345-9. doi: 10.1016/j.yrtph.2012.09.002. Epub 2012 Sep 12. Regul Toxicol Pharmacol. 2012. PMID: 22982732

3

Immunogenicity of mAbs in non-human primates during nonclinical safety assessment.

van Meer PJ, Kooijman M, Brinks V, Gispen-de Wied CC, Silva-Lima B, Moors EH, Schellekens H. van Meer PJ, et al. Among authors: kooijman m. MAbs. 2013 Sep-Oct;5(5):810-6. doi: 10.4161/mabs.25234. Epub 2013 Jun 6. MAbs. 2013. PMID: 23924803 Free PMC article.

4

The risk-based approach to ATMP development - generally accepted by regulators but infrequently used by companies.

Kooijman M, van Meer PJ, Gispen-de Wied CC, Moors EH, Hekkert MP, Schellekens H. Kooijman M, et al. Regul Toxicol Pharmacol. 2013 Nov;67(2):221-5. doi: 10.1016/j.yrtph.2013.07.014. Epub 2013 Aug 7. Regul Toxicol Pharmacol. 2013. PMID: 23933031

5

The value of non-human primates in the development of monoclonal antibodies.

van Meer PJ, Kooijman M, van der Laan JW, Moors EH, Schellekens H. van Meer PJ, et al. Among authors: kooijman m. Nat Biotechnol. 2013 Oct;31(10):882-3. doi: 10.1038/nbt.2709. Nat Biotechnol. 2013. PMID: 24104750 No abstract available.

6

Thirty years of preclinical safety evaluation of biopharmaceuticals: Did scientific progress lead to appropriate regulatory guidance?

Kooijman M, van Meer PJ, Moors EH, Schellekens H. Kooijman M, et al. Expert Opin Drug Saf. 2012 Sep;11(5):797-801. doi: 10.1517/14740338.2012.712110. Epub 2012 Aug 6. Expert Opin Drug Saf. 2012. PMID: 22861668 Review.

7

Why animal studies are still being used in drug development.

Kooijman M. Kooijman M. Altern Lab Anim. 2013 Dec;41(6):P79-81. doi: 10.1177/026119291304100627. Altern Lab Anim. 2013. PMID: 24512237 No abstract available.

8

Nonnatural amino acids for site-specific protein conjugation.

de Graaf AJ, Kooijman M, Hennink WE, Mastrobattista E. de Graaf AJ, et al. Among authors: kooijman m. Bioconjug Chem. 2009 Jul;20(7):1281-95. doi: 10.1021/bc800294a. Bioconjug Chem. 2009. PMID: 19191567 Review.

9

Health Literacy and Disease Knowledge of Patients With Peripheral Arterial Disease or Abdominal Aortic Aneurysm: A Scoping Review.

van Leeuwen GL, Kooijman MA, Schuurmann RCL, van Leeuwen BL, van Munster BC, van der Wal-Huisman H, de Vries JPM. van Leeuwen GL, et al. Among authors: kooijman ma. Eur J Vasc Endovasc Surg. 2024 Mar 27:S1078-5884(24)00285-5. doi: 10.1016/j.ejvs.2024.03.040. Online ahead of print. Eur J Vasc Endovasc Surg. 2024. PMID: 38552837 Free article. Review.

10

Development of novel natto using legumes produced in Europe.

Rocchi R, Zwinkels J, Kooijman M, Garre A, Smid EJ. Rocchi R, et al. Among authors: kooijman m. Heliyon. 2024 Feb 29;10(5):e26849. doi: 10.1016/j.heliyon.2024.e26849. eCollection 2024 Mar 15. Heliyon. 2024. PMID: 38463896 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

95 results

Search Page